Analyzing the requirements of platelets transfusion in stem cell transplant and high dose chemotherapy patients by giving with or without romiplostim.
Not Applicable
- Conditions
- Health Condition 1: D708- Other neutropenia
- Registration Number
- CTRI/2021/12/038468
- Lead Sponsor
- Dr Sachin Suresh Jadhav
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
all patients undergoing autologous. allogenic HSCT and high dose chemotherapy in our department.
Exclusion Criteria
Myelofibrosis (Reticulin for collagen fibrosis >2), any prior history of thromboembolic events.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome: <br/ ><br>1) Number of platelet transfusions until engraftment. <br/ ><br> <br/ ><br>2) Number of days platelet count below 30,000 for patient undergoing <br/ ><br> Number of days platelet count below 30,000 for patient undergoing high dose chemotherapy <br/ ><br>3) Number of platelet transfusion until day +30 and +100 <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: time point weekly once
- Secondary Outcome Measures
Name Time Method 1)Day of Neutrophil engraftment <br/ ><br>2) Day of platelet engraftment <br/ ><br>3) Graft rejection: Chimerism at Day 28,60,100,6 month and Day 365 <br/ ><br>4) Secondary failure of platelet recovery (SFPR): defined as a decline of platelets counts 20 multiplies 10000000000 per L for 7 consecutive days or requiring transfusion support after achieving sustained platelet count greater than or equal 50 multiplies 10000000000 per litre without transfusions for 7 consecutive days after hematopoietic stem cell transplantation.Timepoint: 3 years